Author: tkj

  • Big Coremine Medical Update

    —

    by

    tkj
    in

    Big coremine medical update We have just launched an update of the Coremine Medical GUI and a data update. The GUI has gotten a new look-and-feel and color palette with design elements from our collaboration with the ANTI company. The intention is that the new design should be easier to use, easier to navigate, and allow the…

  • Pathobody Eurostars Project awarded April 2021

    Pathobody Eurostars Project awarded April 2021

    —

    by

    tkj
    in

    Pathobody Eurostars Project awarded April 2021 PubGene was awarded a Eurostars project together with AbSano B.V, Erasmus MC and GenXPro GmbH. The aim of the project is to develop a platform for the recovery of pathogen-specific antibody molecules from exposed patients for the purpose of generating high value monoclonal antibody leads. This will be done…

  • Dialogue with Norwegian health authorities on COVID-19

    —

    by

    tkj
    in

    PubGene has had dialogue with Norwegian health authorities on a possible role for establishing an information channel on the COVID-19 virus, with continuous update on status for the development of vaccines, treatments and documentation of preventive actions in society.

  • Coremine Vitae applied on neuro diseases

    —

    by

    tkj
    in

    PubGene has conducted a first Coremine Vitae within the neuro diseases. We successfully provided an epilepsy patient with information on disease characteristics and drugs.   

  • Coremine Medical upgrade

    —

    by

    tkj
    in

    The Coremine Medical service is upgraded with new features. Please register to the service here: https://coremine.com/medical/

  • Speech at Norways e-health conference

    —

    by

    tkj
    in

    CEO Håvard Hauge presented PubGene and Coremine Vitae at EHiN – Norway’s e-health conference – gathering 1650 national and international delegates. The audience was researchers and people working in healthcare, health informatics, governmental leaders and decision makers.

  • Agreement with Moloklinikken AS

    —

    by

    tkj
    in

    PubGene has signed an innovation contract with the medical clinic Moloklinikken AS. The main objective is to define, develop and streamline the Coremine Vitae biomedical intelligence report as a combined personalised medicine information tool and service. Working with a private clinic like Moloklinikken provides an efficient opportunity to design a new product, since they play…

  • Collaboration with Haukeland University Hospital

    —

    by

    tkj
    in

    PubGene collaborates with the Section for Research and Innovation at Haukeland University Hospital. Haukeland facilitates increased quality and quantity of clinical research, so that the health services can provide a better offer to the population in a cost-effective way. Haukeland provides feedback on the Coremine Vitae (CMV) product, and clinically validates and document its added…

  • PubGene member in Nansen Neuroscience Network

    —

    by

    tkj
    in

    Nansen Neuroscience Network is a non-profit life science organization which are set up to accelerate innovation from Nordic neuroscience research. Much of the work is centred on creating arenas that can trigger synergies between basic and clinical researchers, and where academia and industry can meet and work together. PubGene focus has been primarily on the…

  • Meeting with the Norwegian Ministry of Health

    —

    by

    tkj
    in

    On the 1 of April 2019, PubGene Chair of the Board Eirik Næss-Ulseth met with the State Secretary in the Ministry of Health Anne Grethe Erlandsen. Mr. Næss-Ulseth presented the Coremine Vitae biomedical intelligence report and received very positive feedback. The ministry wanted to be kept updated on the further developments of Coremine Vitae.